Optimal use of β-blockers in high-risk hypertension: A guide to dosing equivalence

Vascular Health and Risk Management

Volumn 6, Issue 1, 2010, Pages 363-372

  McGill, Janet B ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antihypertensive; Atenolol; Blood pressure; Carvedilol; Labetalol; Metoprolol; Nebivolol

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; LABETALOL; METHYLDOPA; METOPROLOL; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; NEBIVOLOL; OXPRENOLOL; PLACEBO; PROPRANOLOL; ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; BIOEQUIVALENCE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CONTROLLED RELEASE FORMULATION; DIZZINESS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; MEDICATION ERROR; MORNING DOSAGE; NAUSEA; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRESCRIPTION; REVIEW; UNSPECIFIED SIDE EFFECT; BLOOD PRESSURE; DOSE CALCULATION; DRUG EFFECT; PATHOPHYSIOLOGY; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG DOSAGE CALCULATIONS; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION; MEDICATION ADHERENCE; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 77955872196     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/vhrm.s6668     Document Type: Review

References (86)

1. Ong KL, Cheung BM, Man YB, Lau C P, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007;49(1):69-75.
2. Moser M. Evolution of the treatment of hypertension from the 1940s to JNC V. Am J Hypertens. 1997;10(3):2S-8S.
3. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6): 1206-1252.
4. Bakris GL. The importance of blood pressure control in the patient with diabetes. Am J Med. 2004;116 Suppl 5A:30S-38S.
5. Tight blood pressure control and risk of macrovascular and microvas cular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317(7160):703-713.
6. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ. 1998;317(7160):713-720.
7. Torre JJ, Bloomgarden ZT, Dickey RA, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of hypertension. Endocr Pract. 2006;12(2):193-222.
8. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2005;28(Suppl 1):S4-S36.
9. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: A consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000;36(3):646-661.
10. Doroodchi H, Abdolrasulnia M, Foster JA, et al. Knowledge and attitudes of primary care physicians in the management of patients at risk for cardiovascular events. BMC Fam Pract. 2008;9:42.
11. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;291(3):335-342.
12. Black HR, Elliott WJ, Neaton JD, et al. Baseline characteristics and early blood pressure control in the CONVINCE trial. Hypertension. 2001;37(1):12-18.
13. CooperDeHoff RM, Handberg EM, Cohen J, et al. Characteristics of contemporary patients with hypertension and coronary artery disease. Clin Cardiol. 2004;27(10):571-576.
14. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003;290(2):199-206.
15. Snow V, Weiss KB, Mottur Pilson C. The evidence base for tight blood pressure control in the management of type 2 diabetes mellitus. Ann Intern Med. 2003;138(7):587-592.
16. Arauz Pacheco C, Parrott MA, Raskin P. Treatment of hypertension in adults with diabetes. Diabetes Care. 2003;26(Suppl 1):S80-S82.
17. Hansson L, Hedner T, Lund Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study. Lancet. 2000;356(9227):359-365.
18. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000;356(9227):366-372.
19. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353(9153):611-616.
20. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: Is it a wise choice? Lancet. 2004;364(9446):1684-1689.
21. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials. BMJ. 2003;326(7404):1427.
22. Neaton JD, Grimm RH Jr, Prineas RJ, et al; Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA. 1993;270(6):713-724.
23. Materson BJ, Reda DJ, Cushman WC. Department of Veterans Affairs single-drug therapy of hypertension study. Revised fgures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Am J Hypertens. 1995;8(2):189-192.
24. Tse WY, Kendall M. Is there a role for beta-blockers in hypertensive diabetic patients? Diabet Med. 1994;11(2):137-144.
25. Fonarow GC. Managing the patient with diabetes mellitus and heart failure: Issues and considerations. Am J Med. 2004;116 Suppl 5A:76S-88S.
26. Bell DS. Use of beta blockers in the patient with diabetes. Endocrinologist. 2003;13(2):116-123.
27. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA. 1982;247(12):1707-1714.
28. CIBISII Investigators and Committees. The Cardiac Insuffciency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet. 1999;353(9146):9-13.
29. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: The CAPRICORN randomised trial. Lancet. 2001;357(9266):1385-1390.
30. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA. 2000;283(15):1967-1975.
31. Majumdar SR. Beta-blockers for the treatment of hypertension in patients with diabetes: Exploring the contraindication myth. Cardiovasc Drugs Ther. 1999;13(5):435-439.
32. Haenni A, Lithell H. Treatment with a beta-blocker with beta 2-agonism improves glucose and lipid metabolism in essential hypertension. Metabolism. 1994;43(4):455-461.
33. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs. metoprolol in patients with type 2 diabetes mellitus and hypertension: A randomized controlled trial. JAMA. 2004;292(18):2227-2236.
34. Bristow MR. Mechanism of action of beta blocking agents in heart failure. Am J Cardiol. 1997;80(11A):26L-40L.
35. Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation. 2000;101(5):558-569.
36. Packer M. Beta adrenergic blockade in chronic heart failure: Principles, progress, and practice. Prog Cardiovasc Dis. 1998;41(1 Suppl 1):39-52.
37. Poole Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): Randomised controlled trial. Lancet. 2003;362(9377):7-13.
38. Wikstrand J, Berglund G, Tuomilehto J. Beta blockade in the primary prevention of coronary heart disease in hypertensive patients. Review of present evidence. Circulation. 1991;84(6 Suppl):VI93-VI100.
39. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain frst choice in the treatment of primary hypertension? A meta analysis. Lancet. 2005;366(9496):1545-1553.
40. Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze GJ. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: The carvedilol-metoprolol study. J Hypertens. 1996;14(4):489-494.
41. Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascu- lar effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med. 1997;126(12):955-959.
42. Schmidt AC, Graf C, Brixius K, Scholze J. Blood pressure lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus: The YESTONO study. Clin Drug Investig. 2007;27(12):841-849.
43. McGill JB, Bakris GL, Fonseca V, et al. Beta blocker use and diabetes symptom score: Results from the GEMINI study. Diabetes Obes Metab. 2007;9(3):408-417.
44. Pedersen ME, Cockcroft JR. The vasodilatory beta-blockers. Curr Hypertens Rep. 2007;9(4):269-277.
45. Stolwijk JA. Responses to the thermal environment. Fed Proc. 1977;36(5):1655-1658.
46. Messerli FH, Grossman E. Beta blockers in hypertension: Is carvedilol different? Am J Cardiol. 2004;93(9A):7B-12B.
47. Yiannakopoulou E, Papadopulos JS, Cokkinos D V, Mountokalakis TD. Adherence to antihypertensive treatment: A critical factor for blood pres- sure control. Eur J Cardiovasc Prev Rehabil. 2005;12(3):243-249.
48. Grant RW, Devita NG, Singer DE, Meigs JB. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care. 2003;26(5):1408-1412.
49. Ubel PA, Jepson C, Asch DA. Misperceptions about beta blockers and diuretics: A national survey of primary care physicians. J Gen Intern Med. 2003;18(12):977-983.
50. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002;359(9311):995-1003.
51. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med. 1993;328(13): 914-921.
52. Croog SH, Levine S, Testa MA, et al. The effects of antihyperten sive therapy on the quality of life. N Engl J Med. 1986;314(26): 1657-1664.
53. Ogihara T, Kuramoto K. Effect of long-term treatment with antihypertensive drugs on quality of life of elderly patients with hypertension: A double blind comparative study between a calcium antagonist and a diuretic. NICSEH Study Group. National Intervention Cooperative Study in Elderly Hypertensives. Hypertens Res. 2000;23(1): 33-37.
54. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296-1310.
55. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens. 2005;23(11):2101-2107.
56. MenaMartin FJ, MartinEscudero JC, SimalBlanco F, Carretero Ares JL, Arzua Mouronte D, Herreros Fernandez V. Health related quality of life of subjects with known and unknown hypertension: Results from the population based Hortega study. J Hypertens. 2003;21(7): 1283-1289.
57. Cheng J W, Kalis MM, Feifer S. Patient-reported adherence to guidelines of the Sixth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Pharmacotherapy. 2001;21(7):828-841.
58. Hulka BS, Cassel JC, Kupper LL, Burdette JA. Communication, compliance, and concordance between physicians and patients with prescribed medications. Am J Public Health. 1976;66(9):847-853.
59. Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens. 2006;19(11):1190-1196.
60. Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol. 2007;100(8):1254-1262.
61. Aursnes I, Osnes JB, Tvete IF, Gasemyr J, Natvig B. Does atenolol differ from other beta-adrenergic blockers? BMC Clin Pharmacol. 2007;7:4.
62. TENORMIN® (atenolol) Tablets [Prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2008 Available at: http://www.realmentalhealth.com/medications/tenormin.asp?view=print. Accessed November 6, 2009.
63. Sarafdis P, Bogojevic Z, Basta E, Kirstner E, Bakris GL. Comparative effcacy of two different beta-blockers on 24-hour blood pressure control. J Clin Hypertens (Greenwich). 2008;10(2):112-118.
64. Neutel JM, Schnaper H, Cheung DG, Graettinger WF, Weber MA. Antihypertensive effects of beta-blockers administered once daily: 24-hour measurements. Am Heart J. 1990;120(1):166-171.
65. Koh KK, Quon MJ, Han SH, et al. Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs. Int J Cardiol. 2010;140(1):73-81.
66. Gupta AK, Dahlof B, Dobson J, Sever PS, Wedel H, Poulter NR. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial - blood pressure lowering arm and the relative infuence of antihypertensive medication. Diabetes Care. 2008;31(5):982-988.
67. Olsen MH, Fossum E, Hoieggen A, et al. Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. J Hypertens. 2005;23(4):891-898.
68. Kendall MJ, Maxwell SR, Sandberg A, Westergren G. Controlled release metoprolol. Clinical pharmacokinetic and therapeutic implications. Clin Pharmacokinet. 1991;21(5):319-330.
69. Lucker P, Moore G, Wieselgren I, Olofsson B, Bergstrand R. Pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK once daily with conventional tablets once daily and in divided doses. J Clin Pharmacol. 1990;30(2 Suppl):S17-S27.
70. Alternatives for metoprolol succinate. Pharmacist's Letter/Prescriber's Letter. 2009;25(3):250-302.
71. MacCarthy E P, Bloomfeld SS. Labetalol: A review of its pharmacology, pharmacokinetics, clinical uses and adverse effects. Pharmacotherapy. 1983;3(4):193-219.
72. Varon J. Treatment of acute severe hypertension: Current and newer agents. Drugs. 2008;68(3):283-297.
73. Podymow T, August P. Hypertension in pregnancy. Adv Chronic Kidney Dis. 2007;14(2):178-190.
74. Kane JA. Labetalol in general practice: A review. Br J Clin Pharmacol. 1982;13(1 Suppl):59S-63S.
75. Wallin JD, Wilson D, Winer N, et al. Treatment of severe hypertension with labetalol compared with methyldopa and furosemide. Results of a long- term, double-blind, multicenter trial. Am J Med. 1983;75(4A):87-94.
76. Cleophas TJ, Agrawal R, Lichtenthal A, Makel W, Fici F. Nationwide effcacy-safety study of nebivolol in mildly hypertensive patients. Am J Ther. 2006;13(3):192-197.
77. Van Bortel LM, Fici F, Mascagni F. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: A meta-analysis. Am J Cardiovasc Drugs. 2008;8(1):35-44.
78. Van Nueten L, Taylor FR, Robertson JI. Nebivolol vs. atenolol and placebo in essential hypertension: A double-blind randomised trial. J Hum Hypertens. 1998;12(2):135-140.
79. Cockcroft J. A review of the safety and effcacy of nebivolol in the mildly hypertensive patient. Vasc Health Risk Manag. 2007;3(6):909-917.
80. COREG CR® (carvedilol phosphate) Extended-release capsules [Prescribing information]. Research Triangle Park, NC: GlaxoSmithKline, Inc.; 2008. Available at: http://us.gsk.com/prod- ucts/assets/us_coregcr.pdf. Accessed November 6, 2009.
81. Henderson LS, Tenero DM, Baidoo CA, et al. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hyperten- sion. Am J Cardiol. 2006;98(7A):17L-26L.
82. Packer M, Lukas MA, Tenero DM, Baidoo CA, Greenberg BH. Pharmacokinetic profle of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction. Am J Cardiol. 2006;98(7A): 39L-45L.
83. Weber MA, Sica DA, Tarka EA, Iyengar M, Fleck R, Bakris GL. Controlled-release carvedilol in the treatment of essential hypertension. Am J Cardiol. 2006;98(7A):32L-38L.
84. Weber MA, Bakris GL, Tarka EA, Iyengar M, Fleck R, Sica DA. Efficacy of a once-daily formulation of carvedilol for the treat- ment of hypertension. J Clin Hypertens (Greenwich). 2006;8(12): 840-849.
85. Tenero DM, Henderson LS, Baidoo CA, et al. Pharmacokinetic proper- ties of a new controlled-release formulation of carvedilol. Am J Cardiol. 2006;98(7A):5L-16L.
86. Fonarow GC. Profile of carvedilol controlled-release: A new once-daily formulation of carvedilol. Expert Opin Pharmacother. 2006;7(18):2533-2546.